Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BAN-BOOT

Financiado

Cerrado

Boronic Acids as a New Strategy to Boost beta-Lactam Antibiotics for the Treatme...

Boronic Acids as a New Strategy to Boost beta-Lactam Antibiotics for the Treatment of Tubercolosis Tuberculosis (TB) is a highly infectious disease caused by Mycobacterium tuberculosis (Mtb), one of the most dangerous aerobic bacteria. The need for long-term treatments and the increase in drug resistance mechanisms make it nece... ver más

15/05/2026

UNIMORE

Presupuesto desconocido

Líder del proyecto

UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMI... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-05-16

HORIZON-MSCA-2023-PF-01-01: MSCA Postdoctoral Fellowships 2023 ExpectedOutcome:Project results are expected to contribute to the following outcomes:

I+D

Cerrada hace 1 año

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

UNIMORE

Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2010-15076 ANTIBIOTICOS INHIBIDORES DE NOVEDOSAS DIANAS TERAPEUTICAS: D... 204K€ Cerrado

BLISS Beta-Lactamase Inhibitors Synthesised through in Situ click... Cerrado

PID2019-105126RB-I00 ULTRAESTRUCTURA Y ALCANCE BIOTECNOLOGICO DE LOS MODULOS DE U... 145K€ Cerrado

deCrYPtion Decrypting Mycobacterium cytochrome P450 CYP physiological... 213K€ Cerrado

VitaminBlock Development of antibacterial compounds that block essential... 150K€ Cerrado

CTQ2010-19073 ESTUDIOS SOBRE RECONOCIMIENTO MOLECULAR DE AMINOGLICOSIDOS P... 103K€ Cerrado

Duración del proyecto: 23 meses Fecha Inicio: 2024-05-16
Fecha Fin: 2026-05-15

Líder del proyecto

UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMI... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Tuberculosis (TB) is a highly infectious disease caused by Mycobacterium tuberculosis (Mtb), one of the most dangerous aerobic bacteria. The need for long-term treatments and the increase in drug resistance mechanisms make it necessary to urgently develop new strategies to combat this potentially lethal pathogen. beta-Lactam Antibiotics (BLA) are the most widely used and safest antibiotics in the clinic and include several classes such as penicillins, cephalosporins and carbapenems. However, historically these agents have not been used to treat TB. There are two mechanisms of resistance to BLA in Mtb: the cell envelope rich in lipoglycans which acts as a barrier for the penetration of many drugs, including BLA, and the expression of BlaC, a specific beta-lactamase enzyme capable of hydrolyze and inactivate the BLA. Recent studies have shown that the combination of meropenem (a beta-lactam carbapenem), amoxicillin (a beta-lactam penicillin) and clavulanate (a beta-Lactamase inhibitor) markedly reduced the Mtb load in the patient’s sputum after two weeks, therefore giving new hope to the use of BLA to tackle the tuberculosis epidemic. This proposal aims to develop new compounds that behave as BLA adjuvant for anti-Mtb treatment with a dual mechanism of action. We will design and synthesize novel Boronic Acid Transition State Inhibitors (BATSIs) as inhibitors of BlaC, the beta-lactamase expressed in Mtb, and investigate whether they can be derivatized to become disrupting agents of Mtb’s unique outer “capsule” made of lipoglycans, to promote better penetration of drugs into the cell. This project will also investigate the possibility of improving the penetration of molecules into the necrotic granuloma formed in vivo as part of the disease process, by developing a lipid-based prodrug strategy. To achieve these specific objectives, the project will be divided into three main work packages, involving a combination of biological, chemical, and analytical expertise.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores